3SBio Inc. (NASDAQ: SSRX), a China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced its unaudited financial results for the first quarter ended March 31, 2012.

3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX".

First Quarter 2012 Financial Highlights:

- Total net revenues increased by 24.5% over the first quarter of 2011 to RMB147.2 million (US$23.4 million), compared to RMB118.2 million (US$18.1 million) in the first quarter of 2011.

- Operating income was RMB35.5 million (US$5.6 million), compared to operating income of RMB25.3 million (US$3.9 million) in the first quarter of 2011.

- Net income was RMB32.6 million (US$5.2 million), compared to net income of RMB22.2 million (US$3.4 million) in the first quarter of 2011.

- Net income per American Depositary Share ("ADS") on a fully-diluted basis was RMB1.44 (US$0.23) compared to net income per ADS on a fully-diluted basis of RMB0.99 (US$0.15) for the first quarter of 2011.

- Cash, cash equivalents, restricted cash and time deposits were RMB790.8 million (US$125.6 million), including restricted cash of RMB0.7 million.

First Quarter 2012 Business Highlights:

- EPIAO, the Company's flagship injectable recombinant human erythropoietin (EPO) product, demonstrated strong growth with net revenue in the first quarter of 2012 rising 21.7% to RMB83.7 million (US$13.3 million), compared to RMB68.8 million (US$10.5 million) in the first quarter of 2011.

- Net revenues for TPIAO, the Company's novel recombinant human thrombopoietin (TPO) product, increased by 23.3% to RMB46.5 million (US$7.4 million) in the first quarter of 2012, compared to RMB37.7 million (US$5.8 million) in the first quarter of 2011.

- Net revenues for Iron Sucrose Supplement increased by 40.6% to RMB6.8 million (US$1.1 million) in the first quarter of 2012, compared to RMB4.9 million (US$0.7 million) in the first quarter of 2011.

- Net export revenues increased by 80.3% to RMB7.6 million (US$1.2 million), compared to RMB4.2 million (US$0.6 million) in the first quarter of 2011.

...